NASDAQ$TOI
Oncology Institute Inc/The · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
The Oncology Institute reported total revenue of $119.8 million and a net loss of $17.0 million for the second quarter of 2025.
The company achieved revenue growth driven by increases in patient services and dispensary segments. Operating expenses rose but SG&A declined year-over-year due to cost discipline. The quarter ended with $30.3 million in cash and cash equivalents.
- Total revenue reached $119.8 million, up 21.5% from Q2 2024.
- Net loss was $17.0 million or $(0.15) per share.
- Dispensary revenue grew 40.8% to $62.6 million on higher prescription volume.
- SG&A expenses decreased 3.5% to $26.9 million reflecting operational efficiencies.
Headline financials
Revenue & EPS history
Oncology Institute · Revenue · Quarterly
$120M
Revenue by segment
Oncology Institute · $120M total across 3 segments · Q2 2025
- Dispensary$62.6M—52.2%
- Patient services$55.9M—46.7%
- Clinical trials & other$1.34M—1.1%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+2.6%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+8.0%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+28.9%
Q3 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +6.8% | +5.8% | +27.9% | |
| Q4 2025 | +8.4% | +37.4% | +17.6% | |
| Q3 2025 | +28.9% | +6.2% | +22.7% | |
| Q1 2025 | +28.3% | +17.3% | +4.2% | |
| Q4 2024 | +24.5% | +14.5% | +189.2% | |
| Q3 2024 | -23.4% | -43.8% | -5.1% | |
| Q2 2024 | -20.4% | -11.1% | -26.9% | |
| Q1 2024 | +3.6% | -26.5% | -46.6% | |
| Q4 2023 | +8.9% | -7.7% | -32.0% | |
| Q3 2023 | +5.7% | +46.6% | -27.6% | |
| Q2 2023 | -10.1% | -13.3% | +28.3% | |
| Q1 2023 | +4.2% | -6.3% | +29.2% | |
| Q4 2022 | +1.9% | -5.8% | -30.6% | |
| Q3 2022 | -4.3% | -35.5% | -66.4% | |
| Q2 2022 | +0.6% | -1.2% | -9.6% | |
| Q1 2022 | -14.7% | -11.8% | -6.5% | |
| Q2 2021 | +10.3% | +31.4% | +48.1% | |
| Q4 2020 | +10.3% | +31.4% | +48.1% | |
| Q4 2021 | -14.6% | +18.5% | +26.5% | |
| Q3 2021 | +0.0% | +10.0% | -23.6% | |
| Q1 2021 | -0.2% | +1.0% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro